Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : Researchers at AstraZeneca Report Findings in Chemical Biology (Identification and Characterization of Dual Inhibitors of the USP25/28...

share with twitter share with LinkedIn share with facebook
share via e-mail
12/07/2017 | 11:57pm CET

Researchers at AstraZeneca Report Findings in Chemical Biology (Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily)

By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Life Science Research - Chemical Biology are discussed in a new report. According to news reporting originating from Cambridge, United Kingdom, by NewsRx correspondents, research stated, "The ubiquitin proteasome system is widely postulated to be a new and important field of drug discovery for the future, with the ubiquitin specific proteases (USPs) representing one of the more attractive target classes within the area. Many USPs have been linked to critical axes for therapeutic intervention, and the finding that USP28 is required for c-Myc stability suggests that USP28 inhibition may represent a novel approach to targeting this so far undruggable oncogene."

Our news editors obtained a quote from the research from AstraZeneca, "Here, we describe the discovery of the first reported inhibitors of USP28, which we demonstrate are able to bind to and inhibit USP28, and while displaying a dual activity against the closest homologue USP25, these inhibitors show a high degree of selectivity over other deubiquitinases (DUBs). The utility of these compounds as valuable probes to investigate and further explore cellular DUB biology is highlighted by the demonstration of target engagement against both USP25 and USP28 in cells. Furthermore, we demonstrate that these inhibitors are able to elicit modulation of both the total levels and the half-life of the c-Myc oncoprotein in cells and also induce apoptosis and loss of cell viability in a range of cancer cell lines. We however observed a narrow therapeutic index compared to a panel of tissue-matched normal cell lines."

According to the news editors, the research concluded: "Thus, it is hoped that these probes and data presented herein will further advance our understanding of the biology and tractability of DUBs as potential future therapeutic targets."

For more information on this research see: Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily. Acs Chemical Biology, 2017;():. (American Chemical Society - www.acs.org; Acs Chemical Biology - www.pubs.acs.org/journal/acbcct)

The news editors report that additional information may be obtained by contacting J.D. Wrigley, Discovery Sciences, IMED Biotech Unit, AstraZeneca , Cambridge, UK. Additional authors for this research include G. Gavory, I. Simpson, M. Preston, H. Plant, J. Bradley, A.U. Goeppert, E. Rozycka, G. Davies, J. Walsh, A. Valentine, K. McClelland, K.E. Odrzywol, J. Renshaw, J. Boros, J. Tart, L. Leach, T. Nowak and R Ward (see also Life Science Research - Chemical Biology).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acschembio.7b00334. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Cambridge, United Kingdom, Chemical Biology, Drugs and Therapies, Life Science Research.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
01/20 ASTRAZENECA : boasts of quadrupling of R&D productivity at biotech unit
01/20 ASTRAZENECA : scores double approvals in Japan for asthma and ovarian cancer
01/20 ASTRAZENECA : X-Chem Enters Expanded Global Drug Discovery And Technology Transf..
01/19 ASTRAZENECA : 0.1% Potential Decrease Indicated by Liberum Capital
01/19 ASTRAZENECA : X-Chem collaborates with AstraZeneca
01/19 ASTRAZENECA : Lynparza receives approval in Japan for the treatment of advanced ..
01/19 ASTRAZENECA : Fasenra receives approval in Japan
01/19 ASTRAZENECA : Reports from AstraZeneca Add New Data to Findings in DNA Research ..
01/19 ASTRAZENECA : Lynparza approved in japan for ovarian cancer
More news
News from SeekingAlpha
01/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 20, 2018
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 AstraZeneca's Lynparza OK'd in Japan for ovarian cancer; shares up 1% premark..
01/18 ARMO BioSciences Proposes Terms For $100 U.S. IPO
01/18 Big Biopharma in the red in early trade
Financials ($)
Sales 2017 21 851 M
EBIT 2017 5 694 M
Net income 2017 2 297 M
Debt 2017 12 304 M
Yield 2017 3,92%
P/E ratio 2017 35,64
P/E ratio 2018 30,52
EV / Sales 2017 4,62x
EV / Sales 2018 4,61x
Capitalization 88 702 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 69,1 $
Spread / Average Target -1,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-2.74%88 702
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132